Immunovant logo

Immunovant

IMVT | NASDAQ
Chart Builder DCF Calculator
$33.28
-$0.90 (-2.63%)
At close: Nov 16, 2026, 4:00 PM ET
$33.28
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-2.63%

Rating

Updated: Nov 16, 2026
39.6
+1.0 pts
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #535/1021 (Top 52%)

Key Statistics

Market Data

Market Cap $6.89B
1D Range
33.04 34.53
52W Range
22.02 44.96

Valuation (TTM)

PE -13
PB 10.48
EV/EBITDA -12.09

Valuation (NTM)

Forward PE N/A
Forward PEG 2.01
Price Target $40.00
Loading financial charts...

Profile

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The compa...

Sector Healthcare
Industry Biotechnology
Employees 315
IPO Date Jun 21, 2019
Fiscal Year April - March

Latest News

Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?

5 days ago · zacks.com

Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum

5 days ago · seekingalpha.com

Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum
Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know

5 days ago · zacks.com

Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know
Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript

7 days ago · seekingalpha.com

Immunovant, Inc. (IMVT) Q2 2027 Earnings Call Transcript
Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study

8 days ago · benzinga.com

Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study
What Immunovant (IMVT) Said on Its Q2 Earnings Call

8 days ago · marketbeat.com

What Immunovant (IMVT) Said on Its Q2 Earnings Call
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026

8 days ago · globenewswire.com

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update

8 days ago · globenewswire.com

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

27 days ago · globenewswire.com

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

1 month ago · gurufocus.com

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Earnings

Next Earnings
Feb 5, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$40.00
Upside
+20.19%
Buy (7)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.